BridgeBio Oncology Therapeutics (BBOT) Free Cash Flow (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Free Cash Flow for 3 years, with the latest figure at -$35.9 million in Q1 2026.

• Quarterly Free Cash Flow fell 83.09% year-over-year to -$35.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$130.4 million (down 76.16% YoY) and the FY2025 annual result came in at -$114.5 million, down 107.89% from the prior year.
• Free Cash Flow grew to -$35.9 million in Q1 2026 per BBOT's latest filing, from -$42.4 million in the prior quarter.
• Over five years, Free Cash Flow peaked at $18.6 million in Q2 2025 and troughed at -$70.6 million in Q3 2025.
• A 3-year average of -$22.8 million and a median of -$19.6 million in 2025 frame the typical range for Free Cash Flow.
• The widest YoY moves for Free Cash Flow: up 63901.0% in 2025, down 3076.38% in 2025.
• Over 3 years, Free Cash Flow stood at -$15.0 million in 2024, then sank by 182.1% to -$42.4 million in 2025, then increased by 15.32% to -$35.9 million in 2026.
• According to Business Quant data, Free Cash Flow over the past three periods registered -$35.9 million, -$42.4 million, and -$70.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.